Rephonic
Artwork for BiotechTV

BiotechTV - News

BiotechTV
Orexin
FDA
Narcolepsy
Takeda
Alkermes
Biogen
Alnylam
Biotechnology
Cedar
Biotech Sector
Pfizer
Xenon
Stoke
China
Clinical Trials
RNA Interference
AI In Biotech
Duchenne Muscular Dystrophy
Axsome Therapeutics
Peanut Allergy

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

PublishesDailyEpisodes404Foundeda year ago
Number of ListenersCategories
Life SciencesScience

Listen to this Podcast

Artwork for BiotechTV

Latest Episodes

The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough respons... more

He describes the science behind Coya's combination therapies, and programs targeting ALS (currently in a phase 2 study), FTD, and Alzheimer's.

He discusses Insmed, IDEAYA, Bicycle, Compass Pathways, Revolution Medicines, Cytokinetics, and CG Oncology

He describes data presented at the Muscular Dystophy Association Annual Meeting which showed biopsy and safety data for 20 patients who have been followed for 90 days and 3 who are out to a year. Plus, explaining the three FDA meetings that are key f... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Recent Guests

Arun Swaminathan
CEO of Coya Therapeutics
Coya Therapeutics
Episode: Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases
Leo Timashev
RBC Capital Markets biotech analyst
RBC Capital Markets
Episode: RBC Biotech Analyst Leo Timashev shares his take on the sector and discusses companies he covers that are in the news
Bo Cumo
President and CEO, Solid Biosciences
Solid Biosciences
Episode: Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead
Christian Tidona
Founder and CEO of BioMedX
BioMedX
Episode: Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners
Michal Preminger
Co-founder involved in BiomedX Venture Labs announcement
BioMedX
Episode: Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners
Michael Henderson
CEO of Apogee Therapeutics
Apogee Therapeutics
Episode: Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis
Jason Cole
CEO Zag Bio
Zag Bio
Episode: Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back
Chip Clark
CEO Altido Therapeutics
Altido Therapeutics
Episode: Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back
Jim MacDonald
Chief Executive of Yellowstone Biosciences
Yellowstone Biosciences
Episode: From London: Yellowstone Biosciences is leveraging an Oxford AML patient biobank to develop an HLA Class II platform of T-cell engagers

Host

Brad
Host of Biotech TV, leading discussions with various biotech leaders and experts.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis
Q: What is the plan for phase 3 regarding dosing schedules?
We will advance both three- and six-month maintenance doses into phase 3, using the induction data and part B data to inform design, and anticipate launching with both regimens to offer physicians options across patient needs.
Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis
Q: How does Zoomilocobalt compare to Dupixent and Epglyphs, and what are the implications for your place in the market?
Zoomilocobalt shows competitive efficacy with a differentiating dosing cadence; Dupixent remains the market leader with broader indications, but our data indicate strong performance in type 2 diseases and potential advantages in dosing convenience that could shift adoption.
Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis
Q: What data are being announced today and why is it important for the atopic dermatitis space?
The data demonstrate rapid itch relief, rapid lesional benefits, and deepening responses with both every-three-month and six-month dosing, suggesting improved dosing can enhance adherence and outcomes, and positioning Zoomilocobalt as a potential front-line therapy alongside established IL-13 inhibitors.
From London: Edward Hodgkin is the Executive Chair of Syncona's 'Slingshot', a platform that takes early stage science from academic labs that isn't ready to be a company and helps matures it
Q: What happens to the academic IP and who owns it as projects mature?
IP is held within a ring-fenced vehicle for each asset, with ongoing involvement from academic founders and tech transfer offices, ensuring the asset can be progressed independently and potentially spun out or partnered when appropriate.
From London: Edward Hodgkin is the Executive Chair of Syncona's 'Slingshot', a platform that takes early stage science from academic labs that isn't ready to be a company and helps matures it
Q: How does Slingshot differ from traditional early-stage venture funds?
Slingshot avoids building standalone companies at the earliest stage and instead manages assets with an experienced drug-development team, choosing to form or partner with a company only when a clinical candidate is ready, which improves capital efficiency.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About BiotechTV

What is BiotechTV about and what kind of topics does it cover?

Content focuses on cutting-edge advancements in biotechnology and healthcare, featuring insights from leading industry figures and discussing the latest innovations in drug development, treatment therapies, and biotech trends. Episodes frequently highlight significant biotechnology conferences, showcasing the perspectives of CEOs and experts on their respective companies and the broader industry landscape. A distinctive aspect is the emphasis on the intersection of technology and biotechnology, along with the incorporation of artificial intelligence in drug discovery and therapy development, which may appeal to listeners interested in the future of health and medical research. The content is ideal for professionals in the life sciences and ... more

Where can I find podcast stats for BiotechTV?

Rephonic provides a wide range of podcast stats for BiotechTV. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to BiotechTV and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does BiotechTV get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for BiotechTV, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for BiotechTV?

Rephonic provides comprehensive predictive audience data for BiotechTV, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does BiotechTV have?

To see how many followers or subscribers BiotechTV has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to BiotechTV?

These podcasts share a similar audience with BiotechTV:

1. Biotech Hangout
2. BioCentury This Week
3. The Long Run with Luke Timmerman
4. The Readout Loud
5. BioVenture VoiCes with Chris Garabedian

How many episodes of BiotechTV are there?

BiotechTV launched a year ago and published 404 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact BiotechTV?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for BiotechTV?

Rephonic pulls ratings and reviews for BiotechTV from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for BiotechTV?

Rephonic provides full transcripts for episodes of BiotechTV. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on BiotechTV?

Recent guests on BiotechTV include:

1. Arun Swaminathan
2. Leo Timashev
3. Bo Cumo
4. Christian Tidona
5. Michal Preminger
6. Michael Henderson
7. Jason Cole
8. Chip Clark

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days